NCT Number: NCT00445731
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant.
PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works compared with standard therapy in cancer patients undergoing a donor bone marrow transplant.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
OBJECTIVES:
Primary
- Compare the effects of a structured walking regimen vs normal standard care on functional status at day 100 after allogeneic bone marrow transplantation in patients with cancer.
Secondary
- Compare the effects of these regimens on patient survival at day 100 and at 1 year after transplantation.
- Compare patient satisfaction with these regimens.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 intervention arms.
- Arm I: Beginning 2-3 days after allogeneic bone marrow transplantation, patients walk on a treadmill or in the hospital hallways twice daily for ≥ 15 minutes. After discharge and continuing for up to 100 days post-transplantation, patients walk once daily for ≥ 30 minutes. Patients record their walking times daily in a journal.
- Arm II: Patients receive no special instructions regarding exercise other than the normal standard of care.
All patients complete questionnaires at discharge and at day 100 post-transplantation measuring daily exercise activities, satisfaction with the recommended walking regimen, and functional status.
PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following malignancies:
- Acute lymphocytic leukemia
- Chronic myelogenous leukemia
- Acute myeloid leukemia
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Myelodysplastic syndromes
- Other malignancy
- Undergoing concurrent allogeneic bone marrow transplantation
PATIENT CHARACTERISTICS:
- Able to walk
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Treatment and study plan
management of therapy complications
Procedureobservation
ProcedurePrimary outcomes
-
Difference in functional status as measured by Karnofsky performance scores at day 0 of allogeneic bone marrow transplantation and at day 100 post-transplantation
Secondary outcomes
-
Survival at day 100 and at 1 year post-transplantation
-
Patient satisfaction with the suggested exercise regimen as measured by the Wilcoxon test using a 5-point rating scale
Sponsors and collaborators
Lead sponsor
University of Minnesota
Other
Registry information
Official study title
A Randomized Trial of the Effect of a Walking Regimen on the Functional Status of Adult Allogeneic Donor Bone Marrow Transplant Patients
Important dates
- Study start
- 2002
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Mar 9, 2007
- Registry last updated
- Sep 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT00079222
Adnexal Diseases, Blast Crisis
Los Angeles, California, United States
View Trial DetailsVaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
NCT00509691
Adnexal Diseases, Blast Crisis
Hershey, Pennsylvania, United States
View Trial DetailsAprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
NCT00248547
Adnexal Diseases, Blast Crisis
Portland, Oregon, United States
View Trial DetailsDonor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
NCT00569283
Adnexal Diseases, Blast Crisis
Dajeon, South Korea
View Trial Details